Anne Alexandra Østgaard, study nurse; Helle Kristine Skjerven, surgeon, Head of the Section for Breast and Endocrine Surgery; Randi Ruud Mathiesen, oncologist, Head of the Centre for Breast Cancer, Head of the Section for Breast Oncology; Bjørn Naume, oncologist, Head of the Clinical Research Group for Breast Cancer; Therese Sørlie, researcher, Head the Department for Cancer Genetics; Vigdis Sandviken Opperud, consultant; Linda Romundstad, radiologist, Department head at the Breast Diagnostic Centre; Eva Mari A. Harboe, cancer nurse, course coordinator; Jon Lømo, pathologist with specialist responsibility for breast. Photo: Per Marius Didriksen Large version
Brandal SHB, Mo T, Fangberget A, Nilsen LB, Geier OM, Bjørndal H, Holmen MM, Engebråten O, Garred Ø, Hole KH, Seierstad T(2026) MRI for Predicting Response and 10-Year Outcome of Neoadjuvant Chemotherapy with or Without Additional Bevacizumab Treatment in HER2-Negative Breast Cancer Cancers (Basel), 18(3) DOI 10.3390/cancers18030393, PubMed 41681863
Hjorth S, Vandraas KF, Trewin-Nybråten CB, Botteri E, Ursin G, Andreassen BK, Støer NC(2026) Anti-HER2 treatment in everyday practice: how we treat older women with breast cancer differently Breast Cancer Res Treat, 215(2), 54 DOI 10.1007/s10549-025-07888-z, PubMed 41498846
Husby M, Frydenberg H, Myklebust TÅ, Skei NV, Solligård E, Thune I, Gustad LT, Furberg AS(2026) Cancer Patients with Sepsis: Prognostic Insights from a Population-Based Cohort Study in Norway Cancer Epidemiol Biomarkers Prev, 35(2), 264-275 DOI 10.1158/1055-9965.EPI-25-1018, PubMed 41324403